Drugs / hgd40
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01470911 | Nov → Dec 2011 | chronic asthma | Sterna Biologicals GmbH & Co. KG | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02079688 | Feb 2014 → Nov 2016 | atopic eczema | Sterna Biologicals GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT01743768 | Dec 2012 → Nov 2013 | asthma | Sterna Biologicals GmbH & Co. KG | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-06-05 | Sterna Biologicals GmbH & Co. KG | Results sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis sterna-biologicals.com ↗
SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis |
| 2013-07-15 | Sterna Biologicals GmbH & Co. KG | Results Bioavailability data of GATA-3-specific DNAzyme demonstrates long-lasting presence in airways of mice, rats, and dogs post inhalation sterna-biologicals.com ↗
Repeated administration did not lead to drug accumulation in plasma of dogs and rats. |
All press releases naming this drug 12 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hgd40 | “The active principle hgd40 of the investigational medicinal product SB010 belongs to a new class of antisense oligonucleotide therapeutics, the 10-23 DNA (deoxyribonucleic...” NCT01470911 ↗2“The active drug substance of the investigational medicinal product SB010 is hgd40.” NCT01743768 ↗ |
| Known as | SB010 | “The active drug substance of the investigational medicinal product SB010 is hgd40.” NCT01743768 ↗ |
| Action | Inhibit | “By cleaving GATA-3 mRNA hgd40 reduces specific cytokine production and thereby reduces key features of allergic airway inflammation.” NCT01470911 ↗ |
| Modality | Antisense oligonucleotide | “belongs to a new class of antisense oligonucleotide therapeutics” NCT01470911 ↗ |
| Route | Inhaled | “inhaled via a controlled breathing system over a 5 to 10 min.” NCT01470911 ↗ |
| Target | GATA3 | “By cleaving GATA-3 mRNA hgd40 reduces specific cytokine production and thereby reduces key features of allergic airway inflammation.” NCT01470911 ↗ |